No CrossRef data available.
Article contents
Safety, Not Only Efficacy Still to be Proven for Controversial New MS Treatment
Published online by Cambridge University Press: 18 February 2016
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Editorial
- Information
- Copyright
- Copyright © Canadian Neurological Sciences Federation 2011
References
1.Smith, CM. Origin and uses of primum non nocere - above all, do no harm! J Clin Pharmacol. 2005;45(4):371–7.CrossRefGoogle ScholarPubMed
2.Kremenchutzky, M, Walt, L. Lack of congruence in the ratings of patients' health status by patients with MS and their physicians. Neurology. 2010;74(9) Suppl 2:A364.Google Scholar
3.Burton, JM, Alikhani, K, Goyal, M, et al. Complications in MS patients after CCSVI procedures abroad (Calgary, AB). Can J Neurol Sci. 2011;38(5):741–6.CrossRefGoogle ScholarPubMed
4.Zamboni, P, Galeotti, R, Menegatti, E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg. 2009;50:1348–58.CrossRefGoogle ScholarPubMed
5.Samson, K. Experimental multiple sclerosis vascular shunting procedure halted at Stanford. Ann Neurol. 2010;67:A13–15.Google Scholar
6.Ludyga, T, Kazibudzki, M, Simka, M, et al. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe? Phlebology. 2010;25(6):286–95.CrossRefGoogle Scholar
7.Petrov, I, Grozdinski, L, Kaninski, G, et al. Safety profile of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Endovasc Ther. 2011;18:314–23.CrossRefGoogle ScholarPubMed
8.www.fda.gov [homepage on the Internet]. What is a serious adverse event? [updated 2011 Jun 23; cited 2011 Jun 30]. Available from: http://www.fda.gov/safety/medwatch/howtoreport/ucm 053087.htm.Google Scholar
You have
Access